Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2008
06/12/2008WO2008070350A2 Methods and compositions related to wrapping of dehydrons
06/12/2008WO2008070346A2 Methods for treating pain with reduced nuasea and vomiting
06/12/2008WO2008070317A2 A method for the treatment of psoriasis
06/12/2008WO2008070313A2 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
06/12/2008WO2008070310A2 Method to enhance tissue regeneration
06/12/2008WO2008070305A2 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as cbl' receptor modulator
06/12/2008WO2008070296A2 System and method for diagnosis and treatment of neuropsychiatric disorders
06/12/2008WO2008070268A2 Pharmaceutical compositions
06/12/2008WO2008070230A2 Methods and compositions for treating central nervos system tumors
06/12/2008WO2008070185A2 Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
06/12/2008WO2008070176A1 Novel hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
06/12/2008WO2008070169A2 Use of carboxyamidotriazole (cai) orotate in macular degeneration
06/12/2008WO2008070161A1 Azepans and methods for making and using same
06/12/2008WO2008070150A1 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
06/12/2008WO2008070136A1 Compositions including triciribine and one or more platinum compounds and methods of use thereof
06/12/2008WO2008070134A1 Inhibitors of akt activity
06/12/2008WO2008070132A2 Methods of use of trk receptor modulators
06/12/2008WO2008070129A2 Compositions and methods for the treatment of inflammatory disease
06/12/2008WO2008070121A1 Intermediate duration neuromuscular blocking agents and antagonists thereof
06/12/2008WO2008070116A2 Topical compositions for treatment of skin conditions
06/12/2008WO2008070100A1 Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
06/12/2008WO2008070095A1 Novel uses
06/12/2008WO2008070086A2 A composition for treatment of connective tissues
06/12/2008WO2008070072A2 Carvedilol forms, compositions, and methods of preparation thereof
06/12/2008WO2008070070A1 Inhibition of osteopontin for treatment of relapsing autoimmnune disease
06/12/2008WO2008070039A2 3 beta-hydroxysteroid dehydrogenase inhibitors
06/12/2008WO2008070011A2 Combination of an hdac inhibitor and an antimetabolite
06/12/2008WO2008070010A2 Hydroxylamine derivatives for the treatment of stroke
06/12/2008WO2008070009A2 Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
06/12/2008WO2008070000A2 Treatment of anxiety with eszopiclone
06/12/2008WO2008069997A1 Substituted diazepan compounds as orexin receptor antagonists
06/12/2008WO2008069972A2 Systems for effecting cessation of tobacco use
06/12/2008WO2008069970A2 Nicotine formulations, kits and systems and methods for their use
06/12/2008WO2008069963A1 Means for improving cognitive functions and memory based on hydrogenated pyrido (4,3-b) indoles (variants), pharmacological means based thereon and method for the use thereof
06/12/2008WO2008069960A2 Separable solid dosage form administration system
06/12/2008WO2008069941A2 Modified release ibuprofen solid oral dosage form
06/12/2008WO2008069938A2 Method of forming a tablet comprising pre-blend of ibupropen and silicon dioxide
06/12/2008WO2008069922A1 Compositions including triciribine and anthracyclin analogs and methods of use thereof
06/12/2008WO2008069921A2 Oral transmucosal nicotine dosage form
06/12/2008WO2008069726A1 Treatment of resistant schizophrenia and other cns disorders by the use of thioxanthenes
06/12/2008WO2008069688A2 Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
06/12/2008WO2008069652A1 Combinations of a sphingolipid and an hmg-coa reductase inhibitor for treating hypercholesterolemia
06/12/2008WO2008069632A1 1,2,3,4-tetrahydroisoquinoline derivatives having effects of preventing and treating degenerative and inflammatory diseases
06/12/2008WO2008069619A1 Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
06/12/2008WO2008069612A1 Pharmaceutical composition comprising amlodipine and losartan
06/12/2008WO2008069611A1 N-phenylamide derivative, process for the preparation thereof, and composition for preventing or treating ischemic diseases comprising same
06/12/2008WO2008069608A1 Method for screening anti-cancer compounds inhibiting function of tm4sf5 and anti-cancer composition containing chalcone compounds
06/12/2008WO2008069546A1 Oral administrative preparation for treating cardiovascular system disease
06/12/2008WO2008069451A1 Improved process for the preparation of clevudine as anti-hbv agent
06/12/2008WO2008069349A1 Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors
06/12/2008WO2008069348A1 Pharmaceutical agent having long-lasting effect of treating arthritic disorders
06/12/2008WO2008069327A1 CRYSTALLINE FORM OF 1- (β-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL] BENZENE HEMIHYDRATE
06/12/2008WO2008069313A1 Method for producing pyrrolidine compound
06/12/2008WO2008069311A1 Tricyclic compound and medical use thereof
06/12/2008WO2008069283A1 Pharmaceutical composition for external application and adhesive skin patch
06/12/2008WO2008069276A1 Cancer therapeutic agent and anti-carcinogenic agent
06/12/2008WO2008069262A1 Film-coated preparation having improved stability
06/12/2008WO2008069242A1 Novel bicyclic heterocyclic compound
06/12/2008WO2008069168A1 Method for production of 2-hydroxymethylpyrrolidin-3,4-diol or intermediate thereof
06/12/2008WO2008069069A1 Amide compound and salt thereof, and biofilm formation inhibitor or biofilm remover using the same
06/12/2008WO2008068866A1 Ophthalmic composition
06/12/2008WO2008068854A1 Therapeutic agent for degenerative arthritis
06/12/2008WO2008068778A2 Extended release pharmaceutical composition of pramipexole
06/12/2008WO2008068777A2 Stable lercanidipine formulation
06/12/2008WO2008068770A2 Pharmaceutical composition containing bicalutamide and a method for its use
06/12/2008WO2008068763A2 Mixture and method for reducing cholesterol using hydrophobic chitosan microparticles
06/12/2008WO2008068762A2 Chitosan formulation for cholesterol reduction in humans
06/12/2008WO2008068751A1 Novel protein kinase modulators and therapeutic uses thereof
06/12/2008WO2008068746A2 Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
06/12/2008WO2008068731A1 Extended release formulations of carvedilol
06/12/2008WO2008068727A2 Pharmaceutical composition comprising candesartan cilexetil
06/12/2008WO2008068621A2 Combination product with ido inhibitor and tumor targeted ifn-gamma
06/12/2008WO2008068615A1 Crystalline forms of ( 3 s ) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid
06/12/2008WO2008068584A2 A heterogeneously configured multiparticulate gastrointestinal drug delivery system
06/12/2008WO2008068548A1 Use of inhibitors of the glycosylation process for the prevention and treatment of genetic diseases
06/12/2008WO2008068540A1 New benzamide derivatives as bradykinin antagonists
06/12/2008WO2008068516A1 Chelating agent
06/12/2008WO2008068507A2 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment
06/12/2008WO2008068477A1 Treatment of cachexia
06/12/2008WO2008068475A1 New crystalline forms
06/12/2008WO2008068470A1 Antibacterial polycyclic urea compounds
06/12/2008WO2008068427A2 Anti-microorganism terpenic composition
06/12/2008WO2008068424A2 Substituted 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one derivatives, preparation thereof and use of same as cannabinoid cb1 receptor ligands
06/12/2008WO2008068423A2 P<0}{0pyrrol derivatives, preparation and use of the same in therapy<0}
06/12/2008WO2008068299A2 Hydrobromide salt of an anti-hiv compound
06/12/2008WO2008068277A1 Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists
06/12/2008WO2008068276A1 Soft gelatin capsules comprising acetylsalicylic acid
06/12/2008WO2008068272A2 Antibacterial quinoline derivatives
06/12/2008WO2008068270A1 Antibacterial quinoline derivatives
06/12/2008WO2008068269A1 Antibacterial quinoline derivatives
06/12/2008WO2008068268A1 Antibacterial quinoline derivatives
06/12/2008WO2008068267A1 Antibacterial quinoline derivatives
06/12/2008WO2008068266A1 Antibacterial quinoline derivatives
06/12/2008WO2008068265A1 Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
06/12/2008WO2008068231A1 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
06/12/2008WO2008068184A1 Indoles which act as via receptor antagonists
06/12/2008WO2008068183A1 Indoles
06/12/2008WO2008068174A1 4,5,6,7-tetrahydro-thieno [2,3-c] pyridines as h3 modulators
06/12/2008WO2008068173A1 4, 5, 6, 7-tetrahydro-thieno [3, 2-c] pyridine derivatives as h3 modulators
06/12/2008WO2008068171A1 Substituted pyrimidines and their use as jnk modulators
1 ... 3222 3223 3224 3225 3226 3227 3228 3229 3230 3231 3232 3233 3234 3235 3236 3237 3238 3239 3240 3241 3242 ... 7860